Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

271.36
+4.671.75%
Pre-market: 271.980.6172+0.23%04:55 EDT
Volume:6.08M
Turnover:1.65B
Market Cap:479.60B
PE:76.66
High:274.94
Open:268.40
Low:266.89
Close:266.69
52wk High:274.94
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.16
T/O Rate:0.34%
Dividend:6.83
Dividend Rate:2.52%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-80.81
PE(LYR):114.98

Loading ...

AbbVie Partners with Iambic to Accelerate AI-Driven Small-Molecule Drug Discovery

Reuters
·
Sep 21

Abbvie and Iambic Announce Collaboration to Accelerate AI-Driven Drug Discovery

THOMSON REUTERS
·
Sep 21

Abbvie - Iambic to Receive Upfront Payment, Milestone Payments, and Tiered Royalties from Collaboration

THOMSON REUTERS
·
Sep 21

Abbvie - Partnership to Accelerate Small Molecule Drug Discovery in Immunology, Neuroscience, Oncology

THOMSON REUTERS
·
Sep 21

Adarx Pharmaceuticals: IPO Price Expected Between $15 and $17 Per Share

Reuters
·
Sep 21

ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO

Dow Jones
·
Sep 21

Drug Developer ADARx Seeks $1.74 Billion Valuation in US IPO

Reuters
·
Sep 21

AbbVie presents new Vraylar data at Psych Congress 2026

TIPRANKS
·
Sep 18

AbbVie Says Real-World Studies Show Vraylar Improves Symptoms in MDD, Bipolar I Depression

Reuters
·
Sep 18

AbbVie Targets Dry Eye Market Upside With New ABBV-444 Trial Update

TIPRANKS
·
Sep 18

US Regulators Urge More Research on Testosterone Therapy for Women as Experts Debate Benefits, Risks

Reuters
·
Sep 18

Niagen Bioscience Names Martin Hendrix Strategic Adviser for Corporate Strategy, M&A

Reuters
·
Sep 17

AbbVie’s Allergan Aesthetics presents clinical data on skin quality improvement

TIPRANKS
·
Sep 17

Abbvie Exec Says Will Present Late-Stage Data for Blood Cancer Drug Etentamig at International Myeloma Society Meeting Later in September - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Existing Portfolio Provides 'Clear Line of Sight' to Very Strong Growth Well into Next Decade - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Apogee Fits 'Very Nicely' with Its Business Development Approach - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Plans to Start Enrolling Apogee's Zumilokibart This Year, Targets Launch in Early 2030 - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Tavapadon U.S. Launch Expected to Have 'Slower Burn' Due to Timing of Medicare Reimbursement - Conf Call

THOMSON REUTERS
·
Sep 15

Testosterone Scripts for Women Rise, Along with Denials and Delays

Reuters
·
Sep 15

RBC Capital Sticks to Their Buy Rating for AbbVie (ABBV)

TIPRANKS
·
Sep 15